Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Efavirenz · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | efavirenz |
| 2 | EXPERIMENTAL | raltegravir 400 mg |
| 3 | EXPERIMENTAL | raltegravir 800 mg |
| Name | Type | Description |
|---|---|---|
| efavirenz | DRUG | tenofovir 245 mg / lamivudine 300 mg / efavirenz 600 mg |
| raltegravir | DRUG | tenofovir 245 mg / lamivudine 300 mg / raltegravir 400 mg |
| Adefovir dipivoxil | DRUG | - |
| Lamivudine | DRUG | - |
| Didanosine | DRUG | - |
Inclusion Criteria: * Adult patients (at least 18 years old) * Plasma HIV RNA \> 1000 copies/ml * HIV-1-infection confirmed by ELISA and Western blot or Immunofluorescence * ART naïve patients or * ART for less than 3 months and more than 6 months ago ; an HIV resistance genotype at baseline showin...
Top 20 of 28 competitors
Efavirenz is a small molecule being developed for the treatment of HIV Infections. It is currently in Phase 2 clinical development and is being studied in combination with other antiretroviral drugs. The drug is intended for use in HIV-infected patients, including those with active tuberculosis.
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that targets the reverse transcriptase enzyme of HIV-1. By binding to this enzyme, it blocks the replication of the virus. This mechanism is being evaluated in clinical trials for the treatment of HIV infections.
Efavirenz is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is conducting Phase 2 clinical trials to evaluate the drug's safety and efficacy in HIV-infected patients.
Efavirenz is currently in Phase 2 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. Two Phase 2 clinical trials have been completed, with a total enrollment of 180 patients, to assess its safety and effectiveness.
Efavirenz has been studied in two completed Phase 2 clinical trials. NCT00002234 evaluated a once-daily combination of adefovir dipivoxil, didanosine, efavirenz, and lamivudine in 25 HIV-infected patients in the United States. NCT00822315 assessed two doses of raltegravir in 155 HIV-1-infected patients receiving rifampin for active tuberculosis in Brazil and France.
Efavirenz is also known by the brand name Sustiva. It is a non-nucleoside reverse transcriptase inhibitor used in the treatment of HIV infections. The drug is being developed by Gilead Sciences and is currently in Phase 2 clinical trials for this indication.